About Index Trending news
Analyze
Pricing
Apellis Pharma

Apellis Pharma

Apellis Pharma

Small Biotech Focusing on Complement Immunotherapy

Elsewhere

Alexa global traffic share

Twitter followers

Latest funding Show all
Venture capital (Series E)
$60,000,000
Epidarex Capital, Sofinnova Ventures, Cormorant Asset Management, +6
Venture capital (Series D)
$47,100,000
Hillhouse Capital Group, Epidarex Capital, Cormorant Asset Management, +3
Employees

Team size

10+
Locations
HQ
Headquarters
$60,000,000 Venture capital (Series E)
bizjournals , businesswire

https://www.bizjournals.com/louisville/news/2017/08/10/local-company-gets-60-million-in-financing.html?ana=twt

$47,100,000 Venture capital (Series D)
FinSMEs

Apellis Pharmaceuticals Completes $47.1M Series D Financing

Health Funding
$32,000,000 Venture capital (Series D)
venturedeal

Apellis Pharma Accepts $32 Million Equity VC